Literature DB >> 2341282

Routine production of 2-deoxy-2-[18F]fluoro-D-glucose by direct nucleophilic exchange on a quaternary 4-aminopyridinium resin.

S A Toorongian1, G K Mulholland, D M Jewett, M A Bachelor, M R Kilbourn.   

Abstract

Resin-supported [18F]fluoride ion has been prepared and applied to a rapid, convenient synthesis of [18F]FDG. "No-carrier-added" [18F]fluoride ion is collected on a quaternary 4-(N,N-dialkylamino)-pyridinium functionalized polystyrene anion exchange resin directly from a [18O]water target, dried by rinsing with acetonitrile, and then reacted with 1,3,4,6-tetra-O-acetyl-2-O-trifluoromethanesulfonyl-beta-D-mann opyrannose. Acidic hydrolysis yields [18F]FDG in a synthesis time of 40 min with overall yields presently averaging above 50%.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2341282     DOI: 10.1016/0883-2897(90)90052-3

Source DB:  PubMed          Journal:  Int J Rad Appl Instrum B        ISSN: 0883-2897


  20 in total

1.  Regional 2-[18F]fluoro-2-deoxy-D-glucose uptake varies in normal lung.

Authors:  T Miyauchi; R L Wahl
Journal:  Eur J Nucl Med       Date:  1996-05

2.  Feasibility study of the use of similarity maps in the evaluation of oncological dynamic positron emission tomography images.

Authors:  T Thireou; G Kontaxakis; L G Strauss; A Dimitrakopoulou-Strauss; S Pavlopoulos; A Santos
Journal:  Med Biol Eng Comput       Date:  2005-01       Impact factor: 2.602

3.  Comparison of the pharmacokinetics of 68Ga-DOTATOC and [18F]FDG in patients with metastatic neuroendocrine tumours scheduled for 90Y-DOTATOC therapy.

Authors:  Sophia Koukouraki; Ludwig G Strauss; Vassilios Georgoulias; Michael Eisenhut; Uwe Haberkorn; Antonia Dimitrakopoulou-Strauss
Journal:  Eur J Nucl Med Mol Imaging       Date:  2006-06-09       Impact factor: 9.236

4.  Software-based fusion of PET and CT images for suspected recurrent lung cancer.

Authors:  Yuji Nakamoto; Michio Senda; Tomohisa Okada; Setsu Sakamoto; Tsuneo Saga; Tatsuya Higashi; Kaori Togashi
Journal:  Mol Imaging Biol       Date:  2008-02-22       Impact factor: 3.488

5.  Comparison of 11C-methionine PET and 18F-FDG PET in patients with primary central nervous system lymphoma.

Authors:  Yoshiro Kawase; Yuka Yamamoto; Reiko Kameyama; Nobuyuki Kawai; Nobuyuki Kudomi; Yoshihiro Nishiyama
Journal:  Mol Imaging Biol       Date:  2011-12       Impact factor: 3.488

6.  Preliminary assessment of fluorine-18 fluorodeoxyglucose positron emission tomography in patients with bladder cancer.

Authors:  S Kosuda; P V Kison; R Greenough; H B Grossman; R L Wahl
Journal:  Eur J Nucl Med       Date:  1997-06

7.  Evaluation of tumour metabolism and multidrug resistance in patients with treated malignant lymphomas.

Authors:  A Dimitrakopoulou-Strauss; L G Strauss; H Goldschmidt; W J Lorenz; W Maier-Borst; G van Kaick
Journal:  Eur J Nucl Med       Date:  1995-05

8.  Detection of gastric cancer using 18F-FLT PET: comparison with 18F-FDG PET.

Authors:  Reiko Kameyama; Yuka Yamamoto; Kunihiko Izuishi; Ryusuke Takebayashi; Masanobu Hagiike; Makiko Murota; Masato Kaji; Reiji Haba; Yoshihiro Nishiyama
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-11-05       Impact factor: 9.236

9.  Evaluation of bone remodeling with (18)F-fluoride and correlation with the glucose metabolism measured by (18)F-FDG in lumbar spine with time in an experimental nude rat model with osteoporosis using dynamic PET-CT.

Authors:  Caixia Cheng; Christian Heiss; Antonia Dimitrakopoulou-Strauss; P Govindarajan; G Schlewitz; Leyun Pan; Reinhard Schnettler; Klaus Weber; Ludwig G Strauss
Journal:  Am J Nucl Med Mol Imaging       Date:  2013-03-08

10.  Evaluation of new bone formation in normal and osteoporotic rats with a 3-mm femur defect: functional assessment with dynamic PET-CT (dPET-CT) using 2-deoxy-2-[(18)F]fluoro-D-glucose ( (18)F-FDG) and (18)F-fluoride.

Authors:  Caixia Cheng; Volker Alt; Antonia Dimitrakopoulou-Strauss; Leyun Pan; Ulrich Thormann; Reinhard Schnettler; Klaus Weber; Ludwig G Strauss
Journal:  Mol Imaging Biol       Date:  2013-06       Impact factor: 3.488

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.